PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | C0037090|respiratory symptoms |
| Sentences | 4 |
| PubMedID- 22215356 | Summary: inhaled aztreonam, a newly formulated lysine salt of the original monobactam antibiotic, is approved for the treatment of respiratory symptoms in patients with cystic fibrosis (cf) who are colonized with pseudomonas aeruginosa. |
| PubMedID- 20431562 | In february 2010, aztreonam for inhalation solution (cayston; gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the us fda to improve respiratory symptoms in patients with cystic fibrosis infected with pseudomonas aeruginosa. |
| PubMedID- 22359344 | Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. |
| PubMedID- 25834733 | Study subjects recorded symptoms and antibiotic use on a daily questionnaire based on the respiratory symptoms domain of the cystic fibrosis questionnaire-revised . |
Page: 1